The safety and efficacy of the combined treatment strategy of infusion of Treg-depleted T lymphocytes and WT1 antigen-specific cancer immunotherapeutic in patients with WT1-positive AML are under evaluation (NCT01513109). Here, WT1 is linked to cancer.